Skip to main content

Table 2 Multivariate analysis of predictors of progression-free survival in patients with DLBCL controlled by Revised International Prognostic Index

From: MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells

Variable

HR

Traning cohort (95% CI)

P value

HR

Validation cohort (95% CI)

P value

R-IPI

12.087

2.684–54.472

0.001

1.916

1.261–2.911

0.002

miR155

7.035

1.497–33.053

0.013

2.230

1.183–4.202

0.013